newsfilter
← Latest News
GlobeNewswire·

Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference

IMMX
  • Immix Biopharma, Inc. will present & host institutional investor meetings at the 37th Annual Piper Sandler Healthcare Conference held Dec. 2-4, 2025, at the Lotte New York Palace Hotel in New York, NY.
  • The Company will offer one-on-one meetings during the conference; interested investors must contact their Piper Sandler representative to request access.
  • A replay link will be posted on the Immix website under the Investors section once available.
  • ImmixBio is a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis & other serious diseases.
  • The lead candidate is NXC-201, a sterically-optimized BCMA-targeted CAR-T cell therapy featuring a "digital filter" to filter out non-specific activation.
  • NXC-201 is being evaluated in the U.S. multi-center Phase 1/2 NEXICART-2 study for relapsed/refractory AL Amyloidosis with a registrational design.
  • Interim results from NEXICART-2 presented at ASCO 2025 met the primary endpoint.
  • NXC-201 holds Regenerative Medicine Advanced Therapy (RMAT) designation from the US FDA & Orphan Drug Designation (ODD) from both the FDA & EMA.
  • The press release includes forward-looking statements regarding NXC-201 benefits, trial timing, results, & business plans that involve risks & uncertainties.
  • Key risks include potential unfavorable trial data, inability to continue the NEXICART-2 study, failure to advance to registration-enabling studies, lack of prior FDA approvals, & potential capital shortages.
  • Contact for media inquiries is Mike Moyer of LifeSci Advisors; investor relations contact is irteam@immixbio.com.